PT2753334T - Inibidores de proteassoma ativados por fap utilizados para o tratamento de tumores sólidos - Google Patents

Inibidores de proteassoma ativados por fap utilizados para o tratamento de tumores sólidos

Info

Publication number
PT2753334T
PT2753334T PT128276862T PT12827686T PT2753334T PT 2753334 T PT2753334 T PT 2753334T PT 128276862 T PT128276862 T PT 128276862T PT 12827686 T PT12827686 T PT 12827686T PT 2753334 T PT2753334 T PT 2753334T
Authority
PT
Portugal
Prior art keywords
fap
treatment
solid tumors
proteasome inhibitors
inhibitors used
Prior art date
Application number
PT128276862T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College filed Critical Tufts College
Publication of PT2753334T publication Critical patent/PT2753334T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
PT128276862T 2011-08-30 2012-08-30 Inibidores de proteassoma ativados por fap utilizados para o tratamento de tumores sólidos PT2753334T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161528824P 2011-08-30 2011-08-30

Publications (1)

Publication Number Publication Date
PT2753334T true PT2753334T (pt) 2022-11-03

Family

ID=47757170

Family Applications (1)

Application Number Title Priority Date Filing Date
PT128276862T PT2753334T (pt) 2011-08-30 2012-08-30 Inibidores de proteassoma ativados por fap utilizados para o tratamento de tumores sólidos

Country Status (14)

Country Link
US (6) US9597410B2 (OSRAM)
EP (2) EP2753334B1 (OSRAM)
JP (2) JP6207509B2 (OSRAM)
CN (2) CN108383893A (OSRAM)
AU (2) AU2012301810B2 (OSRAM)
CA (1) CA2846852C (OSRAM)
DK (1) DK2753334T3 (OSRAM)
ES (1) ES2929179T3 (OSRAM)
HR (1) HRP20221320T1 (OSRAM)
HU (1) HUE060305T2 (OSRAM)
PL (1) PL2753334T3 (OSRAM)
PT (1) PT2753334T (OSRAM)
SI (1) SI2753334T1 (OSRAM)
WO (1) WO2013033396A2 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108383893A (zh) * 2011-08-30 2018-08-10 塔夫茨大学信托人 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂
CN104968657A (zh) * 2012-12-03 2015-10-07 弗·哈夫曼-拉罗切有限公司 被取代的三唑和咪唑化合物
US20170035917A1 (en) * 2013-06-10 2017-02-09 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
JP6468562B2 (ja) * 2013-11-21 2019-02-13 国立大学法人北海道大学 プロテアソーム阻害性化合物
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
CN113786495A (zh) * 2014-06-13 2021-12-14 塔夫茨大学信托人 Fap激活的治疗剂以及其相关用途
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US10640533B2 (en) 2014-07-14 2020-05-05 Centrax International, Inc. Epoxyketone compounds for enzyme inhibition
AU2015306574B2 (en) 2014-08-22 2020-07-23 Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. Specifically activated micromolecular target coupling body in tumor microenvironment and use thereof
CN104231047B (zh) * 2014-08-22 2017-06-16 亚飞（上海）生物医药科技有限公司 水溶性靶向激活的紫杉醇衍生物及其制备和用途
WO2016210054A1 (en) * 2015-06-23 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Novel rhodol fluorophores for near-infrared imaging
CN106588965A (zh) * 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
CN105938123B (zh) * 2015-12-18 2018-09-14 重庆两江药物研发中心有限公司 一种卡非佐米中间体中杂质的检测方法
WO2017156071A1 (en) 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
WO2017222915A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Heterocyclic prolinamide derivatives
EP3472151A4 (en) 2016-06-21 2020-03-04 Orion Ophthalmology LLC CARBOCYCLIC PROLINAMIDE DERIVATIVES
WO2018009417A1 (en) 2016-07-05 2018-01-11 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
JP2020500207A (ja) 2016-09-28 2020-01-09 ブレード・セラピューティクス・インコーポレイテッド カルパインモジュレーター及びそれらの治療上の使用
CN110291401B (zh) 2016-12-14 2023-04-11 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
US11613785B2 (en) 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
EP3606939A4 (en) * 2017-04-04 2021-01-20 F. Hoffmann-La Roche AG SUBSTRATES RECOGNIZED BY FIBROBLAST ACTIVATION PROTEIN (FAP) AND THEIR METHODS OF USE
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
KR102005030B1 (ko) * 2017-10-31 2019-07-29 충북대학교 산학협력단 프로테아좀 억제제를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물
CN108191957B (zh) * 2017-12-30 2021-05-04 浙江大学 三肽大环衍生物及其制备方法和应用
CN111867573A (zh) 2018-01-29 2020-10-30 科诺斯治疗学公司 硼替佐米的瘤内递送
KR20250021601A (ko) * 2018-02-06 2025-02-13 우니베르시타트 하이델베르크 Fap 억제제
CN112513052B (zh) * 2018-08-02 2022-12-16 正大天晴药业集团股份有限公司 氮杂环丁烷衍生物的硼酸酯
US11578101B2 (en) 2018-08-06 2023-02-14 University Of Kentucky Research Foundation Proteasome inhibitors
GB201820320D0 (en) * 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
US20240092831A1 (en) * 2019-10-11 2024-03-21 Mayo Foundation For Medical Education And Research Proteasome Inhibitors
CN111235221B (zh) * 2020-01-22 2022-08-05 北京大学第一医院 一种fap抑制剂的活性检测方法
CZ309380B6 (cs) * 2020-03-30 2022-10-26 Ústav organické chemie a biochemie AV ČR v. v. i Sloučeniny pro inhibici fibroblastového aktivačního proteinu
CN115968411A (zh) * 2020-06-17 2023-04-14 犹他大学研究基金会 基于生物标记的用于蛋白酶体抑制剂治疗的患者选择
TW202239407A (zh) 2020-12-17 2022-10-16 瑞典商阿斯特捷利康公司 Ｎ－（２－（４－氰基四氫噻唑－３－基）－２－側氧基乙基）－喹啉－４－甲醯胺
CN116981479A (zh) * 2020-12-17 2023-10-31 塔夫茨大学信托人 Fap激活的放射治疗诊断法以及与之相关的用途
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CN118255835A (zh) * 2022-12-27 2024-06-28 上海美悦生物科技发展有限公司 三肽环氧酮化合物、药物组合物及其制备方法和用途
WO2025159301A1 (ko) * 2024-01-24 2025-07-31 서울대학교산학협력단 섬유아세포 활성화 단백질에 의해 활성화되는 프로드러그 화합물

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
CA1341029C (en) 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
WO1995025223A1 (en) 1994-03-11 1995-09-21 Wilson Greatbatch Ltd. Low power electromagnetic pump
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
BR9813233A (pt) 1997-09-29 2000-08-22 Point Therapeutics Inc Estimulação de células hematopoéticas in vitro
WO1999038501A2 (en) 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
WO1999056753A1 (en) 1998-05-04 1999-11-11 Point Therapeutics, Inc. Hematopoietic stimulation
JP2002517401A (ja) 1998-06-05 2002-06-18 ポイント セラピューティクス， インコーポレイテッド 環状ボロプロリン化合物
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
DE60000413D1 (de) 1999-02-11 2002-10-10 Battelle Memorial Inst Columbu Stromversorgung
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU2002360453C1 (en) 2001-11-26 2009-06-18 The Brigham And Women's Hospital, Inc. Methods for treating autoimmune disorders, and reagents related thereto
JP4771661B2 (ja) 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
CA2484551A1 (en) * 2002-04-30 2003-11-13 Trustees Of Tufts College Smart pro-drugs of serine protease inhibitors
EP1578362A4 (en) 2002-07-09 2008-11-05 Point Therapeutics Inc COMBINATION THERAPY WITH A BOROPROLINE COMPOUND
CA2525574C (en) 2003-05-15 2015-06-30 Trustees Of Tufts College Stable analogs of peptide and polypeptide therapeutics
KR101292707B1 (ko) 2004-02-23 2013-08-02 트러스티즈 오브 터프츠 칼리지 디펩티딜펩티다아제 ⅳ의 억제제
US20060063719A1 (en) 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
JP2008545661A (ja) 2005-05-19 2008-12-18 ジェネンテック・インコーポレーテッド 線維芽細胞活性化タンパク質阻害剤化合物および
BRPI0612607A2 (pt) * 2005-07-05 2010-12-07 Tufts College inibidores de alfa proteìna de ativação de fibroblasto
AU2006201635A1 (en) * 2005-10-20 2007-05-10 Ludwig Institute For Cancer Research Novel inhibitors and methods for their preparation
CA2633803A1 (en) * 2005-12-19 2007-09-07 Trustees Of Tufts College Soft protease inhibitors and pro-soft forms thereof
US20080004286A1 (en) * 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
EP2139337A4 (en) * 2007-03-20 2012-09-19 Tufts College FIBROBLAST ACTIVATION PROTEIN INHIBITOR AND METHODS OF USE THEREOF
WO2008116053A2 (en) * 2007-03-20 2008-09-25 Trustees Of Tufts College Fap-activated chemotherapeutic compounds, and methods of use thereof
WO2009006473A2 (en) * 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
EP2527347A1 (en) * 2007-08-06 2012-11-28 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
CA2696579C (en) * 2007-08-17 2017-01-24 Boehringer Ingelheim International Gmbh Purine derivatives for use in the treatment of fab-related diseases
WO2009111470A2 (en) * 2008-03-03 2009-09-11 Kansas State University Research Foundation Protease assay
JP5801585B2 (ja) 2011-03-30 2015-10-28 株式会社ケーヒン 燃料噴射制御システム
CN108383893A (zh) * 2011-08-30 2018-08-10 塔夫茨大学信托人 用于治疗实体瘤的fap-活化的蛋白酶体抑制剂

Also Published As

Publication number Publication date
US12214047B2 (en) 2025-02-04
US20250367304A1 (en) 2025-12-04
US11065339B2 (en) 2021-07-20
US20190054181A1 (en) 2019-02-21
US20210379190A1 (en) 2021-12-09
US9597410B2 (en) 2017-03-21
DK2753334T3 (da) 2022-11-07
EP4144354A1 (en) 2023-03-08
HUE060305T2 (hu) 2023-02-28
US10517955B2 (en) 2019-12-31
WO2013033396A3 (en) 2014-05-08
US20200323994A1 (en) 2020-10-15
EP2753334A2 (en) 2014-07-16
CN108383893A (zh) 2018-08-10
AU2017204121A1 (en) 2017-07-06
EP2753334B1 (en) 2022-10-19
US20160346401A1 (en) 2016-12-01
SI2753334T1 (sl) 2023-01-31
CA2846852A1 (en) 2013-03-07
PL2753334T3 (pl) 2022-12-12
US20140255300A1 (en) 2014-09-11
HRP20221320T1 (hr) 2023-01-06
JP2018016629A (ja) 2018-02-01
AU2012301810B2 (en) 2017-06-01
CN103945856A (zh) 2014-07-23
JP2014527070A (ja) 2014-10-09
WO2013033396A2 (en) 2013-03-07
JP6207509B2 (ja) 2017-10-04
EP4144354B1 (en) 2025-11-26
CA2846852C (en) 2021-01-12
AU2012301810A1 (en) 2014-04-10
ES2929179T3 (es) 2022-11-25
US9956297B2 (en) 2018-05-01
EP2753334A4 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
PT2753334T (pt) Inibidores de proteassoma ativados por fap utilizados para o tratamento de tumores sólidos
CY2021031I2 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
PT2523661T (pt) Inibidores de nkcc para o tratamento de autismo
BR112014000033A2 (pt) compostos para o tratamento de dependência química
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
CO6791604A2 (es) Compuesto para liberación controlada de agentes de tratamiento de pozos
HUE057264T2 (hu) Eljárás új IDH1 inhibitorok elõállítására
IL243976A0 (en) kdm1a inhibitors for disease treatment
EP2911669C0 (en) SYNERGIC COMBINATION OF IMMUNOLOGICAL INHIBITORS FOR THE TREATMENT OF CANCER
CO7030960A2 (es) Inhibidores de pak para el tratamiento de los trastornos de proliferación celular
BR112014032105A2 (pt) método para o tratamento de câncer
ES2603028T8 (es) Procedimiento para la preparación de (Z)-alfa-fluoro-beta-amino-acrilaldehídos sustituidos
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
ITMI20131636A1 (it) Apparecchiatura di reazione per il trattamento di rifiuti e procedimento relativo
BR112013022523A2 (pt) uso de glicopirrolato para o tratamento de taquicardia
BR112013029484A2 (pt) método para o tratamento de tumores sólidos avançados
HUE045947T2 (hu) Formuláció IBS kezelésére
BR112013031702A2 (pt) 1-piperazino-3-fenil indanos deuterados para o tratamento de esquizofrenia
BR112014029487A2 (pt) método para o tratamento cosmético
BR112013028890A2 (pt) composições e métodos para o tratamento de câncer
BR112013030930A2 (pt) composições farmacêuticas combinadas para o tratamento de tumores
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
PT2822552T (pt) Método e composto melhorados para o tratamento de sintomas da menopausa